EG Life Sciences

FEBRUARY 15, 2023

The year 2022 reflected a transformative path for the drug development industry. Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drug developers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment.

Drug Development 52

Drug Development FDA Approval Virus Drugs 52

Conversations in Drug Development Trends

MARCH 20, 2024

In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial.

Clinical Trials 52

Clinical Trials Trials Compliance Treatment 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

PerkinElmer

FEBRUARY 18, 2021

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings. It is an ongoing debate.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

Conversations in Drug Development Trends

NOVEMBER 21, 2023

Since the advent of modern medicine, the scientific community has developed more than 3,000 drugs for thousands of diseases. Despite significant progress, there are more than 6,500 rare diseases without a single approved treatment. There are so many patients suffering from diseases that have no treatments.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The workshop is also discussed in Cell & Gene here and here.

Therapies 59

Therapies Engineering Production FDA 59

Conversations in Drug Development Trends

MARCH 12, 2024

For a more in-depth look at biomarkers, check out our white paper. In addition to being well-understood, the methods for collecting non-specific markers of disease burden are frequently cost-effective and robust, enabling your clinical program to collect data seamlessly.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72